Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06623136 | A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 40 | Elpiscience (Suzhou) Biopharma, Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT07193641 | A Study on Using SFRT With Standard Treatment for Oligoprogressive NSCLC | recruiting | Phase 2 | 25 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 26, 2025 |
| clinicaltrials |
| NCT05037331 | Osimertinib for Advanced EGFR-positive NSCLC Patients | recruiting | — | 58 | National University Hospital, SingaporeOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06448572 | EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.(EXLIBRIS) | recruiting | Phase 1 / Phase 2 | 21 | University Hospital, LilleOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT07193160 | Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy | not yet recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 0 | Sep 25, 2025 | clinicaltrials |
| NCT05163028 | A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations | active not recruiting | Phase 1 | 42 | HUYABIO International, LLC.INDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT05485974 | A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation | active not recruiting | Phase 1 | 44 | HUYABIO International, LLC.INDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT06448910 | Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC | active not recruiting | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT07190027 | Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial | not yet recruiting | Phase 1 / Phase 2 | 246 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Sep 24, 2025 | clinicaltrials |
| NCT06210815 | A Study of HLX42 in Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 102 | Shanghai Henlius BiotechINDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT03289780 | Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects(INSIGHT) | active not recruiting | — | 5,006 | Biodesix, Inc.INDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04171492 | Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules(ALTITUDE) | active not recruiting | — | 2,000 | Biodesix, Inc.INDUSTRY | 2 | Sep 19, 2025 | clinicaltrials |
| NCT05880706 | A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 198 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06205706 | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 4 | Sep 19, 2025 | clinicaltrials |
| NCT07060950 | Analysis of Circulating Tumor Markers in Blood - ALCINA 5(ALCINA 5) | not yet recruiting | N/A | 620 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07154368 | JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs. | not yet recruiting | Phase 3 | 207 | Guangzhou JOYO Pharma Co., LtdINDUSTRY | 0 | Sep 19, 2025 | clinicaltrials |
| NCT07182708 | High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC(HOFIBREN) | not yet recruiting | Phase 2 | 62 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT02788461 | Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy(PET-BOOST) | active not recruiting | N/A | 78 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT03306680 | SUNSET: SBRT for Ultra-central NSCLC- a Safety and Efficacy Trial | active not recruiting | Phase 1 | 30 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT03485378 | Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease(ASPIRE-ILD) | active not recruiting | N/A | 39 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 2 | Sep 18, 2025 | clinicaltrials |
| NCT04547504 | PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %(PERSEE) | active not recruiting | Phase 3 | 349 | University Hospital, BrestOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT04892849 | Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy(ST-ICI02) | recruiting | — | 200 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07179445 | Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant Immunotherapy | not yet recruiting | — | 300 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 33 | Vyriad, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07161882 | ALG-LungCancerRegistry (SAFRO2202)(SAFRO2202) | recruiting | — | 3,750 | Société Algérienne de Formation et de Recherche en OncologieOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07177092 | Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer(SURGAN-TKI) | not yet recruiting | Phase 2 | 118 | Jianxing HeOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT07177105 | Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC(SURGAN-ICI) | not yet recruiting | Phase 2 | 118 | Jianxing HeOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT03958240 | Deciphering Mechanisms Underlying Cancer Immunogenicity(DECIDE) | recruiting | N/A | 1,100 | Institut Claudius RegaudOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06020066 | SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI | active not recruiting | Phase 2 | 202 | Fudan UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06840782 | First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.(OliGRAIL) | recruiting | Phase 3 | 124 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07173244 | A Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid Tumors | not yet recruiting | — | 300 | Tianjin First Central HospitalOTHER | 0 | Sep 15, 2025 | clinicaltrials |
| NCT02617186 | Robotic Lobectomy vs. Thoracoscopic Lobectomy for Early Stage Lung Cancer: RCT | active not recruiting | N/A | 446 | St. Joseph's Healthcare HamiltonOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07169903 | Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT(STAR012) | not yet recruiting | Phase 3 | 587 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07169994 | A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 414 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT05091190 | Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers(MADMAS) | active not recruiting | N/A | 75 | Hospices Civils de LyonOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06732193 | Fissios© and Postoperative Complications (FPoC Trial)(FPoC) | recruiting | N/A | 560 | Carlos Alfredo Fraile Olivero, MD, PhD.OTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05277844 | Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC(TARGET-01) | recruiting | Phase 2 | 106 | Tata Memorial HospitalOTHER_GOV | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05278052 | Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC(TARGET-02) | recruiting | Phase 3 | 190 | Tata Memorial HospitalOTHER_GOV | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05653882 | A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | active not recruiting | Phase 1 | 552 | Asher Biotherapeutics, Inc.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07166003 | Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer(NeoIP-Lung) | recruiting | — | 500 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT06512207 | A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer | recruiting | N/A | 80 | Jinzhou Medical UniversityOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07162883 | Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 3 | 122 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 9, 2025 | clinicaltrials |
| NCT06262321 | Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax(DRO2301) | recruiting | Phase 2 | 48 | University of RochesterOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06868485 | A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 40 | Wayshine Biopharm, Inc.INDUSTRY | 3 | Sep 8, 2025 | clinicaltrials |
| NCT07150598 | Immune-Marker Platform for Patients With Advanced Lung Cancer(IMPALUX) | not yet recruiting | — | 500 | Technische Universität DresdenOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07150663 | Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer | recruiting | Phase 3 | 134 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07158840 | AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment(AGA TKI NSCLC) | not yet recruiting | Phase 2 | 60 | AkesoINDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07159646 | Athletic Intervention After THoracic surgEry for luNg cAncer: a Pilot Study | not yet recruiting | N/A | 10 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Sep 8, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Sep 26, 2025source: clinicaltrials